To extend our findings, we made use of the subcutaneous KPB6G12C model which develops immune cold tumours, due to low number of clonal single-nucleotide variants, that do not respond to combination of KRASG12C inhibition and anti-PD-1 treatment even though they are highly sensitive to KRASG12C inhibition24,26. Here, PDCD1 is linked to neoplasm.